Structure of AZD-4547
CAS No.: 1035270-39-3
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC50 values of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1035270-39-3 |
Formula : | C26H33N5O3 |
M.W : | 463.57 |
SMILES Code : | O=C(NC1=NNC(CCC2=CC(OC)=CC(OC)=C2)=C1)C3=CC=C(N4C[C@@H](C)N[C@@H](C)C4)C=C3 |
InChI Key : | VRQMAABPASPXMW-HDICACEKSA-N |
Pubchem ID : | 51039095 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H319-H335-H413 |
Precautionary Statements: | P261-P273-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
UM004 | 0–10 μM | 8 days | AZD4547 significantly suppressed FGF2-induced resistance of UM004 cells to BET inhibitors. | PMC6365926 |
UM001 | 0–10 μM | 8 days | AZD4547 significantly suppressed FGF2-induced resistance of UM001 cells to BET inhibitors. | PMC6365926 |
Adult mouse primary cardiomyocytes | 5 μM | 1 h | AZD-4547 pretreatment prevents HG-induced inflammatory responses, fibrotic protein induction, and cellular hypertrophy | PMC10985127 |
Rat primary cardiomyocytes | 5 μM | 1 h | AZD-4547 pretreatment prevents HG-induced inflammatory responses, fibrotic protein induction, and cellular hypertrophy | PMC10985127 |
H9C2 cells | 5 μM | 1 h | AZD-4547 pretreatment mimics FGFR1 knockdown in preventing HG-induced inflammatory responses, fibrotic protein induction, and cellular hypertrophy | PMC10985127 |
H520 cells | 1 μM | 24 h | To investigate the effect of AZD-4547 on autophagy in FGFR1-amplified NSCLC cells, results showed that AZD-4547 induced increased autophagic activity. | PMC5450166 |
H1581 cells | 1 μM | 24 h | To investigate the effect of AZD-4547 on autophagy in FGFR1-amplified NSCLC cells, results showed that AZD-4547 induced increased autophagic activity. | PMC5450166 |
OMM1.3 | 0–10 μM | 8 days | AZD4547 significantly suppressed FGF2-induced resistance of OMM1.3 cells to BET inhibitors. | PMC6365926 |
JNA fibroblasts | 0 to 25 µg/mL | 72 h | AZD4547 inhibited JNA fibroblast proliferation, migration, and invasion through inhibition of FGFR and downstream signaling. | PMC5827962 |
L929 | 0.1 μM | 24 h | AZD4547 at 0.1 μM effectively blocked TZ-induced necroptosis in L929 cells, demonstrating its inhibition in TLR3 and TLR4-mediated necroptosis. | PMC10042809 |
HT29 | 0.019 μM | 24 h | AZD4547 at 0.019 μM significantly reduced TSZ-induced cell death in HT29 cells, demonstrating its dose-dependent necroptosis inhibition. | PMC10042809 |
TOV-21G | 0.5 μM | 24 h | AZD4547 at 0.5 μM effectively blocked TSZ-induced cell necrosis, demonstrating its potential as a necroptosis inhibitor. | PMC10042809 |
KatoIII cells | 100 nM | 14 days | To identify kinases that modulate cellular sensitivity to FGFR2 inhibition and validate the roles of ILK and CSK in regulating cell sensitivity to AZD4547. | PMC6510732 |
Human hepatic stellate cells (HSCs) | 10 pg/mL | 24 h | To evaluate the expression of proliferation, fibrosis, and angiogenesis markers in HSCs after rhFGF1 treatment. Results showed that rhFGF1 treatment increased the mRNA expression of these markers compared to untreated cells. | PMC9234675 |
Human cholangiocyte cell line (H69) | 10 pg/mL | 24 h | To evaluate the expression of proliferation, fibrosis, senescence, and angiogenesis markers in H69 cells after rhFGF1 treatment. Results showed that rhFGF1 treatment increased the mRNA expression of these markers compared to untreated cells. | PMC9234675 |
A2780-CP20 cells | 1 µM | 48 and 72 hours | To evaluate the effect of AZD4547 on the proliferation of A2780-CP20 cells, results showed no significant effect on resistant cells | PMC10811874 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | STZ-induced type 1 diabetic mice | Oral | 5 mg/kg | Every other day for 20 weeks | AZD-4547 treatment prevents diabetes-induced cardiac inflammation, fibrosis, and dysfunction | PMC10985127 |
Nude mice | UM001 xenograft model | Oral gavage | 5 mg/kg | Once daily for 23 days | AZD4547 alone had a moderate effect on reducing UM001 tumor volume, but the combination of PLX51107 and AZD4547 significantly suppressed tumor growth. | PMC6365926 |
Mice | TNF-induced systemic inflammatory response syndrome (SIRS) model | Oral | 5 and 10 mg/kg | 1 hour before administration, continuous observation | AZD4547 at 5 and 10 mg/kg significantly reduced TNF-induced hypothermia and death, demonstrating its protective effects in the SIRS model. | PMC10042809 |
Nude mice | U87MG xenograft model | Intraperitoneal injection | 30 mg/kg | Once daily for two weeks | AZD4547 was less effective than CYY292 in inhibiting U87MG tumor growth and caused weight loss in nude mice. | PMC10425802 |
Mice | Osteosarcoma lung metastasis model | Oral | 12.5 mg/kg | Daily for 14 days | To study the effects of AZD4547 on osteosarcoma lung metastasis, results showed that AZD4547 significantly reduced the number and size of metastatic lung nodules | PMC4688957 |
Nude mice | MCF-7 xenograft model | Oral | 12.5 mg/kg | Once daily for six weeks | To evaluate the inhibitory effect of AZD4547 in combination with AZD5363 on tumor growth in MCF-7 xenograft models. The results showed that AZD4547 alone did not significantly inhibit tumor growth, but its anti-tumor effect was slightly enhanced when combined with AZD5363. | PMC3979036 |
Mice | Bile duct–ligated (BDL) mice and multidrug resistance 2 knockout (Mdr2−/−) mice | Intraperitoneal injection | 100 ng/kg | Once daily for 7 days | To evaluate the effect of AZD4547 on hepatic fibrosis, biliary proliferation, and inflammation in BDL and Mdr2?/? mice. Results showed that AZD4547 treatment significantly reduced hepatic fibrosis, biliary proliferation, and inflammation. | PMC9234675 |
BALB/c nude mice | Intraperitoneal xenograft model | Oral | 25 mg/kg | Once daily until the end of the experiment | To evaluate the anti-tumor effect of AZD4547 in the resistant A2780-CP20 cell xenograft model, results showed no significant effect on the resistant model | PMC10811874 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02299999 | Metastatic Breast Cancer | Phase 2 | Recruiting | December 2022 | France ... More >> Institut de Cancérologie de l'Ouest/Paul Papin Recruiting Angers, France Contact: Mario CAMPONE, MD mario.campone@ico.unicancer.fr Principal Investigator: Mario CAMPONE, MD Institut Sainte-Catherine Recruiting Avignon, France Contact: Alice Mege, MD a.mege@isc84.org Principal Investigator: Alice Mege, MD Polyclinique Bordeaux Nord Aquitaine Recruiting Bordeaux, France, 33077 Contact: Nadine DOHOLLOU, MD n.dohollou@bordeauxnord.com Contact: Nadine DOHOLLOU, MD Institut Bergonié Recruiting Bordeaux, France Contact: Hervé Bonnefoi, MD h.bonnefoi@bordeaux.unicancer.fr Principal Investigator: Hervé Bonnefoi, MD Centre François Baclesse Recruiting Caen, France Contact: Christelle Lévy, MD c.levy@baclesse.unicancer.fr Principal Investigator: Christelle Lévy, MD Centre Jean Perrin Recruiting Clermont-Ferrand, France Contact: Marie-Ange Mouret Reynier, MD marie-ange.mouret-reynier@cjp.fr Principal Investigator: Marie-Ange Mouret Reynier, MD Ch Alpes Leman Not yet recruiting Contamine Sur Arve, France, 74130 Contact: Carol ALLIOT, MD calliot@ch-alpes-leman.fr Contact: Carol ALLIOT, MD Centre Georges François Leclerc Recruiting Dijon, France, 21079 Contact: Nicolas Isambert, MD nisambert@cgfl.fr Principal Investigator: Nicolas Isambert, MD Chd Vendee Recruiting La Roche-sur-Yon, France, 85925 Contact: Tifenn L'Haridon, MD tifenn.lharidon@chd-vendee.fr Contact: Tifenn L'Haridon, MD Centre Oscar Lambret Recruiting Lille, France Contact: Nuria KOTECKI, MD Principal Investigator: Nuria KOTECKI, MD Chu Dupuytren Not yet recruiting Limoges, France, 87000 Contact: Laurence VENAT-BOUVET, MD laurence.venat-bouvet@chu-limoges.fr Contact: Laurence VENAT-BOUVET, MD Hopital Privé Jean Mermoz Not yet recruiting Lyon, France, 69008 Contact: Olfa DERBEL, MD o.derbelmermoz@gmail.com Contact: Olfa DERBEL, MD Centre Hospitalier Lyon Sud Recruiting Lyon, France Contact: Benoit You, MD Principal Investigator: Benoit You, MD Centre Léon Bérard Recruiting Lyon, France Contact: Thomas Bachelot, MD thomas.bachelot@lyon.unicancer.fr Principal Investigator: Thomas Bachelot, MD Institut Paoli Calmettes Recruiting Marseille, France Contact: Anthony Gonçalves, MD goncalvesa@ipc.unicancer.fr Principal Investigator: Anthony Gonçalves, MD Institut Régional du Cancer Montpellier Val d'Aurelle Recruiting Montpellier, France Contact: William Jacot, MD william.jacot@icm.unicancer.fr Principal Investigator: William Jacot, MD Centre Alexis Vautrin Recruiting Nancy, France Contact: Elisabeth Luporsi, MD e.luporsi@nancy.unicancer.fr Principal Investigator: Elisabeth Luporsi, MD Institut de Cancérologie de l'Ouest/ René Gauducheau Recruiting Nantes, France Contact: Mario Campone, MD mario.campone@ico.unicancer.fr Principal Investigator: Mario Campone, MD Centre Antoine Lacassagne Recruiting Nice, France Contact: Jean-Marc Ferrero, MD jean-marc.ferrero@nice.unicancer.fr Principal Investigator: Jean-Marc Ferrero, MD Institut Curie Recruiting Paris, France Contact: Marie-Paule Sablin, MD mariepaule.sablin@curie.fr Principal Investigator: Marie-Paule Sablin, MD Centre Eugène Marquis Recruiting Rennes, France Contact: Claudia Lefeuvre-Plesse, MD c.lefeuvre@rennes.unicancer.fr Principal Investigator: Claudia Lefeuvre-Plesse, MD Centre Henri Becquerel Recruiting Rouen, France Contact: Jean-Christophe Théry, MD Principal Investigator: Jean-Christophe Théry, MD Institut Curie Recruiting Saint-Cloud, France Contact: Florence COUSSY, MD florence.coussy@curie.fr Principal Investigator: Florence COUSSY, MD Hopitaux Universitaire de Strasbourg - Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD philippe.barthelemy@chru-strasbourg.fr Principal Investigator: Philippe BARTHELEMY, MD Hopitaux Du Leman Recruiting Thonon-les-Bains, France, 74200 Contact: Francesco DEL PIANO, MD f-delpiano@ch-hopitauxduleman.fr Contact: Francesco DEL PIANO, MD Institut Claudius Regaud Recruiting Toulouse, France Contact: Florence Dalenc, MD dalenc.florence@iuct-oncopole.fr Principal Investigator: Florence Dalenc, MD Gustave Roussy Recruiting Villejuif, France Contact: Monica Arnedos, MD Monica.ARNEDOS@gustaveroussy.fr Principal Investigator: Monica Arnedos, MD Sub-Investigator: Fabrice André, MD Less << |
NCT02664935 | Non-Small Cell Lung Cancer ... More >> Carcinoma, Squamous Cell Adenocarcinoma Less << | Phase 2 | Recruiting | September 2021 | United Kingdom ... More >> Belfast City Hospital, Belfast Health and Social Care Trust Recruiting Belfast, United Kingdom Contact: Paula Scullin Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom, B15 2GW Contact: Gary Middleton, MB BS MD FRCP Principal Investigator: Gary Middleton, MB BS MD FRCP Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust Recruiting Birmingham, United Kingdom Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: David Gilligan, BSc (Hons) MB BChir FRCP FRCR cctc@addenbrookes.nhs.uk Principal Investigator: David Gilligan, BSc (Hons) MB BChir FRCP FRCR Velindre Cancer Centre, Velindre NHS Trust Recruiting Cardiff, United Kingdom, CF14 2TL Contact: Alison Brewster, BSC MB BCh FRCR MD 029 2061 5888 Principal Investigator: Alison Brewster, BSC MB BCh FRCR MD Edinburgh Cancer Centre, Western General Hospital Recruiting Edinburgh, United Kingdom, EH4 2XU Contact: Melanie Mackean, MB ChB MRCP MSc MD Principal Investigator: Melanie Mackean, MB ChB MRCP MSc MD Royal Devon and Exeter Hospital Recruiting Exeter, United Kingdom Contact: Elizabeth Toy Principal Investigator: Elizabeth Toy Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom, G12 0YN Contact: Noelle O'Rourke, BA MB MCh MA MCRP MD FRCR CCST Principal Investigator: Noelle O'Rourke, BA MB MCh MA MCRP MD FRCR CCST St. James' University Hospital, Leeds Teaching Hospital NHS Trust Recruiting Leeds, United Kingdom, LS9 7TF Contact: Clive Mulatero, BA MB BCh MA PhD FRCP Principal Investigator: Clive Mulatero, BA MB BCh MA PhD FRCP Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust Recruiting Leicester, United Kingdom Contact: Dean Fennell Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SW3 6JJ Contact: Sanjay Popat Principal Investigator: Sanjay Popat, BSc MB BS MRCP PhD FRCP Charing Cross Hospital, Imperial College Healthcare NHS Trust Recruiting London, United Kingdom Contact: Conrad Lewanski Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust Recruiting London, United Kingdom Contact: James Spicer St Bartholomew's Hospital, Barts Health NHS Trust Recruiting London, United Kingdom Contact: John Conibear University College Hospital, University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom The Christie Hospital, The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom Contact: Yvonne Summers Sir Bobby Robson Cancer Trial Research Centre, The Newcastle upon Tyne Hospitals Recruiting Newcastle, United Kingdom, NE7 7DN Contact: Alastair Greystoke Principal Investigator: Alastair Greystoke, BSc MBChB MRCP MSc PhD Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Recruiting Oxford, United Kingdom Contact: Denis Talbot Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Sarah Danson Southampton General Hospital, University Hospital Southampton NHS Foundation Trust Recruiting Southampton, United Kingdom, SO16 6YD Contact: Christian Ottensmeier clinicaltrials@uhs.nhs.uk Principal Investigator: Christian Ottensmeier Less << |
NCT02117167 | Non-small Cell Lung Cancer Met... More >>astatic Less << | Phase 2 | Recruiting | February 2022 | France ... More >> Centre Hospitalier Henri Duffau Recruiting Avignon, France Contact: Nicolas CLOAREC, MD nicolas.cloarec@ch-avignon.fr Principal Investigator: Nicolas CLOAREC, MD Centre Hospitalier Universitaire de Besancon - Hopital Jean Minjoz Recruiting Besancon, France Contact: Virginie WESTEEL, MD virginie.westeel@univ.fcomte.fr Principal Investigator: Virginie WESTEEL, MD Hôpital Avicenne Recruiting Bobigny, France Contact: Boris DUCHEMANN, MD boris.duchemann@aphp.fr Principal Investigator: Boris DUCHEMANN, MD Institut Bergonié Recruiting Bordeaux, France Contact: François Chomy, MD f.chomy@bordeaux.unicancer.fr Principal Investigator: François Chomy, MD Hôpital Ambroise Paré Recruiting Boulogne Billancourt, France Contact: Etienne GIROUX LEPRIEUR, MD etienne.giroux-leprieur@aphp.fr Principal Investigator: Etienne GIROUX LEPRIEUR, MD Hospices Civils de Lyon- Hôpital Louis Pradel Recruiting Bron, France Contact: Nicolas Girard, MD nicolas.girard@chu-lyon.fr Principal Investigator: Nicolas Girard, MD Centre François Baclesse Recruiting Caen, France Contact: Radj Gervais, MD r.gervais@baclesse.unicancer.fr Principal Investigator: Radj Gervais, MD CHU Caen Recruiting Caen, France Contact: Gérard Zalcman, MD zalcman-g@chu-caen.fr Principal Investigator: Gérard Zalcman, MD Chu de Caen - Hopital Cote de Nacre Recruiting Caen, France Contact: Jeannick MADELAINE, MD madelaine-j@chu-caen.fr Principal Investigator: Jeannick MADELAINE, MD Hôpital Louis Pasteur Recruiting Chartres, France Contact: Claire Lethrosne, MD clethrosne@ch-chartres.fr Principal Investigator: Claire Lethrosne, MD centre Jean Perrin Recruiting Clermont-Ferrand, France Contact: Xavier Durando, MD xavier.durando@cjp.fr Principal Investigator: Xavier Durando, MD CHU Clermont Ferrand - Hôpital Gabriel Montpied Recruiting Clermont-Ferrand, France Contact: Henri Janicot, MD hjanicot@chu-clermontferrand.fr Principal Investigator: Henri Janicot, MD Hopitaux Civils de Colmar Recruiting Colmar, France Contact: Lionel MOREAU, MD lionel.moreau@ch-colmar.fr Principal Investigator: Lionel MOREAU, MD Centre Hopsitalier Intercommunal de Créteil Recruiting Créteil, France Contact: Isabelle Monnet, MD isabelle.monnet@chicreteil.fr Principal Investigator: Isabelle Monnet, MD Centre Georges François Leclerc Recruiting Dijon, France Contact: Bruno Coudert, MD bcoudert@cgfl.fr Principal Investigator: Bruno Coudert, MD CHU Grenoble Recruiting Grenoble, France Contact: Denis Moro-Sibilot, MD Dmoro-Sibilot@chu-grenoble.fr Principal Investigator: Denis Moro-Sibilot, MD Chd Vendee Recruiting La Roche Sur Yon, France Contact: Tifenn L'HARIDON, MD Principal Investigator: Tifenn L'HARIDON, MD CH du Mans Recruiting Le Mans, France Contact: Olivier Molinier, MD omolinier@ch-lemans.fr Principal Investigator: Olivier Molinier, MD Centre Oscar Lambret Recruiting Lille, France Contact: Eric Dansin, MD e-dansin@o-lambret.fr Principal Investigator: Eric Dansin, MD CHRU de Lille Recruiting Lille, France Contact: Alexis Cortot, MD Alexis.CORTOT@CHRU-LILLE.FR Principal Investigator: Alexis Cortot, MD Centre Léon Bérard Recruiting Lyon, France Contact: Maurice Pérol, MD maurice.perol@lyon.unicancer.fr Principal Investigator: Maurice Pérol, MD Hôpital Nord Recruiting Marseille, France Contact: Fabrice Barlesi, MD fabrice.barlesi@ap-hm.fr Principal Investigator: Fabrice Barlési, MD Institut Paoli Calmettes Recruiting Marseille, France Contact: Anne MADROSZYK, MD madroszyka@ipc.unicancer.fr Principal Investigator: Anne MADROSZYK, MD Institut de cancérologie de l'Ouest Recruiting Nantes, France Contact: Jaafar Bennouna, MD jaafar.bennouna@ico.unicancer.fr Principal Investigator: Jaafar Bennouna, MD Centre Antoine Lacassagne Recruiting Nice, France Contact: Josiane OTTO, MD josiane.otto@nice.unicancer.fr Principal Investigator: Josiane OTTO, MD Chr Orleans Recruiting Orleans, France Contact: Hugues MOREL, MD hugues.morel@chr-orleans.fr Contact: , MD Principal Investigator: Hugues MOREL AH-HP Hôpital Saint Louis Recruiting Paris, France Contact: Damien Pouessel, MD damien.pouessel@sls.aphp.fr Principal Investigator: Damien Pouessel, MD AP-HP Hôpital Cochin Recruiting Paris, France Contact: Jeanne Chapron, MD jeanne.chapron@cch.aphp.fr Principal Investigator: Jeanne Chapron, MD AP-HP Hôpital Européen Georges Pompidou Withdrawn Paris, France AP-HP Hôpital Tenon Recruiting Paris, France Contact: Marie Wislez, MD marie.wislez@tnn.aphp.fr Principal Investigator: Marie Wislez, MD Institut Curie Recruiting Paris, France Contact: Catherine Daniel, MD catherine.daniel@curie.fr Principal Investigator: Catherine Daniel, MD Centre Hospitalier de Pau Recruiting PAU, France Contact: Aldo RENAULT, MD aldo.renault@ch-pau.fr Principal Investigator: Aldo RENAULT, MD Centre Hospitalier Lyon Sud Recruiting Pierre Bénite, France Contact: Jean-Pierre Souquet, MD pierre-jean.souquet@chu-lyon.fr Principal Investigator: Jean-Pierre Souquet, MD CHR Pontchailloux Withdrawn Rennes, France Chru Strasbourg - Nouvel Hopital Civil Recruiting Strasbourg, France Contact: Philippe BARTHELEMY, MD Principal Investigator: Philippe BARTHELEMY, MD CHI de Toulon - Hôpital Sainte-Musse Recruiting Toulon, France Contact: Xavier TCHIKNAVORIAN, MD Principal Investigator: Xavier TCHIKNAVORIAN, MD CHU Toulouse -Hôpital Larrey Recruiting Toulouse, France Contact: Julien Mazières, MD mazieres.j@chu-toulouse.fr Principal Investigator: Julien Mazières, MD Hôpital Bretonneau Recruiting Tours, France Contact: Eric Pichon, MD e.pichon@chu-tours.fr Principal Investigator: Eric Pichon, MD Gustave Roussy Recruiting Villejuif, France Contact: Benjamin Besse, MD Benjamin.BESSE@gustaveroussy.fr Principal Investigator: Benjamin Besse, MD Sub-Investigator: Jean-Charles Soria, MD Less << |
NCT02546661 | Muscle Invasive Bladder Cancer | Phase 1 | Recruiting | March 27, 2020 | - |
NCT01202591 | FGFR Inhibition, Pharmacokinet... More >>ics, Biomarkers ER+ Breast Cancer Less << | Phase 1 Phase 2 | Completed | - | Belgium ... More >> Research Site Leuven, Belgium Research Site Namur, Belgium Czech Republic Research Site Brno, Czech Republic Research Site Praha 4, Czech Republic France Research Site Villejuif Cedex, France Germany Research Site Erlangen, Germany Research Site München, Germany Research Site Rostock, Germany Hungary Research Site Budapest, Hungary Research Site Kaposvár, Hungary Research Site Nyíregyháza, Hungary Research Site Szeged, Hungary Italy Research Site Genova, Italy Research Site Lido di Camaiore, Italy Research Site Roma, Italy Romania Research Site Cluj Napoca, Romania United Kingdom Research Site Dundee, United Kingdom Research Site London, United Kingdom Research Site Manchester, United Kingdom Research Site Oxford, United Kingdom Research Site Sutton, United Kingdom Less << |
NCT02154490 | Recurrent Squamous Cell Lung C... More >>arcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7 Less << | Phase 2 Phase 3 | Recruiting | April 1, 2022 | - |
NCT02465060 | Advanced Malignant Solid Neopl... More >>asm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer Less << | Phase 2 | Recruiting | - | - |
NCT01202591 | - | Completed | - | - | |
NCT01457846 | Gastro-oesophageal Junction Ca... More >>ncer Gastric Cancer Less << | Phase 2 | Terminated | - | - |
NCT01457846 | - | Terminated | - | - | |
NCT01795768 | Gastric Cancer ... More >> Oesophageal Cancer Breast Cancer Squamous Cell Carcinoma of the Lung Less << | Phase 2 | Unknown | September 2015 | United Kingdom ... More >> Royal Marsden NHS Foundation Trust Recruiting London and Surrey, Surrey, United Kingdom, SM2 5PT Contact: Angela Gillbanks +44(0)2086613156 angela.gillbanks@rmh.nhs.uk Principal Investigator: David Cunningham, MD FRCP Sub-Investigator: Nicholas Turner, MA MRCP PhD Sub-Investigator: Sanjay Popat, BSc MBBS MRCP PhD Sub-Investigator: Elizabeth Smyth, MB MRCP MSc Less << |
NCT00979134 | Cancer Advanc... More >>ed Solid Malignancies Less << | Phase 1 | Completed | - | - |
NCT01791985 | Breast Cancer | Phase 1 Phase 2 | Active, not recruiting | June 2017 | United Kingdom ... More >> Queen's Hospital, Burton-on-Trent Burton-on-Trent, Staffs, United Kingdom, DE13 0RB Russells Hall Hospital, West C8 Admin Office, 2nd Floor Dudley, West Midlands, United Kingdom, DY1 2HQ Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Breast Cancer Research Unit, PO Box 97, Hills Road, Cambridge, United Kingdom, CB2 0QQ Greater Glasgow Health Board, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, United Kingdom, G12 0YN Imperial College Healthcare NHS Trust, Charing Cross Hospital,1st Floor, Department of Medical Oncology, Fulham Palace Road London, United Kingdom, W6 8RF The Christie NHS Foundation Trust, Wilmslow Road, Withington Manchester, United Kingdom, M20 4BX The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, High Heaton Newcastle upon Tyne, United Kingdom, NE7 7DN Poole Hospital NHS Foundation Trust, Top Floor, Linac Office, Poole, United Kingdom, BH15 2JB Less << |
NCT01213160 | Cancer Advanc... More >>ed Solid Malignancies Less << | Phase 1 | Completed | - | Japan ... More >> Research Site Chuo-ku, Japan Research Site Nagoya-shi, Japan Research Site Sapporo-shi, Japan Less << |
NCT01824901 | Recurrent Non-small Cell Lung ... More >>Cancer Squamous Cell Lung Cancer Less << | Phase 1 Phase 2 | Completed | - | United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 United States, Massachusetts Eastern Cooperative Oncology Group (ECOG) Research Base Brookline, Massachusetts, United States, 02445-7648 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Less << |
NCT02965378 | FGFR1 Gene Amplification ... More >> FGFR1 Gene Mutation FGFR2 Gene Amplification FGFR2 Gene Mutation FGFR3 Gene Amplification FGFR3 Gene Mutation Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7 Less << | Phase 2 Phase 3 | Active, not recruiting | April 1, 2022 | - |
NCT02824133 | Recurrent IDHwt Gliomas With F... More >>GFR3-TACC3 Fusion Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Less << | Phase 1 Phase 2 | Suspended(Intermedary analysis... More >> of 12 first patients' data results) Less << | September 2018 | France ... More >> Neuro onsology unit - Groupe Hospitalier Pitié-Salpêtrière Paris, France, 75013 Less << |
NCT01824901 | - | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.16mL 0.43mL 0.22mL |
10.79mL 2.16mL 1.08mL |
21.57mL 4.31mL 2.16mL |